Presentation Held Tuesday, May 6 at 2:35 p.m.
GENEVA, Switzerland (April 29, 2008) – Leading omega-3 supplier EPAX AS confirmed today that Dr. Morten Bryhn will be presenting a Supplier Seminar detailing a favorable link between docosahexaenoic acid (DHA) and health issues associated with Type 2 Diabetes at Vitafoods International, the global nutraceutical event.
Dr. Bryhn's presentation will be held Tuesday, May 6 at 14:35 (2:35 p.m.) in the Supplier Seminar Theatre.
"The polyunsaturated fatty acid DHA, which is found in fish fat and fish phospholipids, has been associated with a large number of genes interacting in the utilization of fat components in our diets," said Dr. Bryhn.
Obesity rates have risen dramatically throughout the world. This has led to a marked increase in metabolic syndrome, a clustering of risk factors for cardiovascular disease characterized by elevated blood pressure, elevated triglycerides, low HDL-cholesterol ("good cholesterol"), a tendency to increase blood clotting, reduced peripheral insulin effects, so-called insulin resistance and a systemic pro-inflammatory state also called "silent inflammation," Dr. Bryhn noted.
"An increased use of DHA concentrates to reduce the risk of developing metabolic syndrome in obese people is foreseen as well as the development of new drugs based on DHA derivatives for treatment of patients with type 2 diabetes mellitus," said Dr. Bryhn.
About EPAX AS:
EPAX AS offers concentrated marine omega-3 oils in the business-to-business segment under the brand name EPAX(R), available in a wide range of top-quality formulas with different EPA/DHA ratios and concentrations focused on specific health conditions, available in TG and EE versions. EPAX AS is headquartered in Aalesund with a global sales office in Lysaker/Oslo, Norway. Its production facility in Aalesund is GMP-approved by the Norwegian Medicines Agency for the manufacturing of API products. EPAX is part of the Austevoll Seafood ASA group – a globally integrated pelagic fishery specialist with operations in Chile, Norway and Peru (www.auss.no). All of EPAX's business efforts reflect the company's core commitment: Purity - Quality - Innovation. These values represent EPAX's commitment to offering products that are safe, pure and of consistent quality. EPAX(R) specifications limits for environmental pollutants and oxidation by-products are well below those set by global authorities' limits. All EPAX formulas are backed by clinical studies.
# # #